Trial Profile

Trastuzumab in a Neo-Adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms TRAIN

Most Recent Events

01 Mar 2017 Results reporting the efficacy and toxicity of weekly paclitaxel-trastuzumab-carboplatin as neo-adjuvant treatment, published in the European Journal of Cancer.
10 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
23 Oct 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com